Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Cytokinetics Amends ALS Therapy Trial After Mistake

Cytokinetics Inc., the developer of an experimental drug for amyotrophic lateral sclerosis, said it will increase the number of patients in a trial of the therapy after some were given a placebo by mistake.

After talking with regulators, Cytokinetics expanded the trial to include about 680 patients and updated the statistical methods section. The changes are expected to increase trial costs by about $5 million this year and next, the South San Francisco, California-based company said today in a statement.

A programming error controlling study drug assignment caused 58 patients that should have been treated with the drug, tirasemtiv, to instead be given a placebo, Cytokinetics said July 8. More than 500 patients have been enrolled so far in the trial, which is in the second of three phases generally required for regulatory approval.

The company said enrollment is expected to be completed in the second half of this year, with results available in early 2014. ALS, or Lou Gehrig’s disease, is a fatal breakdown of the central nervous system with no known cure.

Cytokinetics fell 4.5 percent to $13.10 at the close in New York. The shares have tripled this year.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.